Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biomechanical Regulation of Angiogenesis during Tumor Progression

Award Number: R00CA230202
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2018
PERIOD OF PERFORMANCE END DATE: 02/29/2024

Group Awards By:

View Award Description

Biomechanical Regulation of Angiogenesis during Tumor Progression - Project Summary During cancer progression, angiogenesis is upregulated to supply the ever-increasing metabolic demands of the growing tumor. While targeting tumor-associated angiogenesis has been a therapeutic strategy for many years, these techniques demonstrate limited effectiveness in many cancer types. We believe this may be due to limited understanding of the biomechanical environment of the tumor. Recently cancer-associated fibroblasts (CAFs) have been shown to be key regulators of the peritumoral environment responsible for secreting several growth factors that control angiogenesis and metastasis. CAFs exhibit a myofibroblast-like phenotype, with increases in alpha-smooth muscle actin and Snail1. We hypothesized that CAF-generated increases in biomechanical strains enhance tip cell activation and drive angiogenesis in the tumor microenvironment. Our initial work has demonstrated that CAF biomechanical activity is directly related to the vascularization potential of these cells in in vitro models of vascular growth, and that inhibiting the mechanotransductive pathways in these cells abrogated their ability to support the formation of blood vessel networks. Continuing this research will further elucidate the roles of biomechanics during tumor progression as well as reveal potential targets for novel anti-cancer therapeutic strategies. During the K99 portion of the grant, we will (1) investigate the role of CAF biomechanics in an in vivo angiogenic mouse model and (2) optimize a microfluidic platform for angiogenesis studies that will allow for isolation and interrogation of biomechanical parameters. The proposed microtissue platform will be highly innovative in that it allows for independent control of several key biomechanical properties. Importantly, this phase of the grant will complement the PI’s career development by incorporating training in cancer cell biology analysis techniques as well as mouse models of cancer progression. During the R00 portion of the grant, we will investigate how endothelial cells respond to mechanical cues from CAFs utilizing the microtissue model previously developed. Finally we will investigate potential anti-cancer therapeutic strategies targeting CAF biomechanical promotion of tumor development in a mouse model of breast cancer. Ultimately this work has significant implications for not only understanding biomechanics of cancer progression but also the development of a unique in vitro microtissue model that will permit interrogation of biomechanics in a truly original manner. The training, techniques, and approaches developed during this grant should open several new avenues for future studies and will allow the PI to transition into a fully-independent investigator.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$48,690 )
2024	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Biology Research	000	5	6/17/2024	NON-COMPETING CONTINUATION	-$48,690
														Subtotal = -$48,690

Issue Date FY: 2022 ( Subtotal = $249,000 )
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Biology Research	000	5	1/26/2022	NON-COMPETING CONTINUATION	$249,000
														Subtotal = $249,000

Issue Date FY: 2021 ( Subtotal = $207,407 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Biology Research	000	4	2/11/2021	NON-COMPETING CONTINUATION	$207,407
														Subtotal = $207,407

Issue Date FY: 2020 ( Subtotal = $290,593 )
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Biology Research	000	3	5/7/2020	EXTENSION WITH OR WITHOUT FUNDS	$249,000
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Biology Research	001	3	8/4/2020	EXTENSION WITH OR WITHOUT FUNDS	$41,593
														Subtotal = $290,593

Grand Total All Awards = $698,310

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biomechanical Regulation of Angiogenesis during Tumor Progression

Award Number: R00CA230202

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2018

PERIOD OF PERFORMANCE END DATE: 02/29/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer